Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Accumulated Depreciation for 6 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 40.69% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, up 40.69% year-over-year, with the annual reading at $7.0 million for FY2025, 40.69% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $7.0 million at Janux Therapeutics, up from $6.5 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $7.0 million in Q4 2025, with the low at $39000.0 in Q2 2021.
  • Average Accumulated Depreciation over 5 years is $2.8 million, with a median of $2.4 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation skyrocketed 759.09% in 2022, then soared 40.69% in 2025.
  • Over 5 years, Accumulated Depreciation stood at $131000.0 in 2021, then soared by 641.98% to $972000.0 in 2022, then soared by 199.79% to $2.9 million in 2023, then surged by 69.94% to $5.0 million in 2024, then surged by 40.69% to $7.0 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $7.0 million, $6.5 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.